Cargando…
T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer
In recent years, several newly identified T helper (T(H)) cell subsets, such as T(H)9, T(H)17, and T(H)22 cells, and their respective cytokine products, IL-9, IL-17, and IL-22, have been reported to play critical roles in the development of chronic inflammation in the colorectum. Since chronic infla...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787935/ https://www.ncbi.nlm.nih.gov/pubmed/31637216 http://dx.doi.org/10.3389/fonc.2019.01002 |
_version_ | 1783458386741821440 |
---|---|
author | Cui, Guanglin |
author_facet | Cui, Guanglin |
author_sort | Cui, Guanglin |
collection | PubMed |
description | In recent years, several newly identified T helper (T(H)) cell subsets, such as T(H)9, T(H)17, and T(H)22 cells, and their respective cytokine products, IL-9, IL-17, and IL-22, have been reported to play critical roles in the development of chronic inflammation in the colorectum. Since chronic inflammation is a potent driving force for the development of human colorectal cancer (CRC), the contributions of T(H)9/IL-9, T(H)17/IL-17, and T(H)22/IL-22 in the pathogenesis of CRC have recently become an increasingly popular area of scientific investigation. Extensive laboratory and clinical evidence suggests a positive relationship between these new T(H) subsets and the growth and formation of CRC, whereas, administration of IL-9, IL-17, and IL-22 signaling inhibitors can significantly alter the formation of colorectal chronic inflammation or CRC lesions in animal models, suggesting that blocking these cytokine signals might represent promising immunotherapeutic strategies. This review summarizes recent findings and currently available data for understanding the vital role and therapeutic significance of T(H)9/IL-9, T(H)17/IL-17, and T(H)22/IL-22 in the development of colorectal tumorigenesis. |
format | Online Article Text |
id | pubmed-6787935 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67879352019-10-21 T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer Cui, Guanglin Front Oncol Oncology In recent years, several newly identified T helper (T(H)) cell subsets, such as T(H)9, T(H)17, and T(H)22 cells, and their respective cytokine products, IL-9, IL-17, and IL-22, have been reported to play critical roles in the development of chronic inflammation in the colorectum. Since chronic inflammation is a potent driving force for the development of human colorectal cancer (CRC), the contributions of T(H)9/IL-9, T(H)17/IL-17, and T(H)22/IL-22 in the pathogenesis of CRC have recently become an increasingly popular area of scientific investigation. Extensive laboratory and clinical evidence suggests a positive relationship between these new T(H) subsets and the growth and formation of CRC, whereas, administration of IL-9, IL-17, and IL-22 signaling inhibitors can significantly alter the formation of colorectal chronic inflammation or CRC lesions in animal models, suggesting that blocking these cytokine signals might represent promising immunotherapeutic strategies. This review summarizes recent findings and currently available data for understanding the vital role and therapeutic significance of T(H)9/IL-9, T(H)17/IL-17, and T(H)22/IL-22 in the development of colorectal tumorigenesis. Frontiers Media S.A. 2019-10-04 /pmc/articles/PMC6787935/ /pubmed/31637216 http://dx.doi.org/10.3389/fonc.2019.01002 Text en Copyright © 2019 Cui. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cui, Guanglin T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title | T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title_full | T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title_fullStr | T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title_full_unstemmed | T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title_short | T(H)9, T(H)17, and T(H)22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer |
title_sort | t(h)9, t(h)17, and t(h)22 cell subsets and their main cytokine products in the pathogenesis of colorectal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787935/ https://www.ncbi.nlm.nih.gov/pubmed/31637216 http://dx.doi.org/10.3389/fonc.2019.01002 |
work_keys_str_mv | AT cuiguanglin th9th17andth22cellsubsetsandtheirmaincytokineproductsinthepathogenesisofcolorectalcancer |